← Product Code [DAE](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAE) · K974111 # QUIDEL CH50 EQ EIA (K974111) _Quidel Corp. · DAE · Jul 29, 1998 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAE/K974111 ## Device Facts - **Applicant:** Quidel Corp. - **Product Code:** [DAE](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAE.md) - **Decision Date:** Jul 29, 1998 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5240 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Indications for Use The QUIDEL CH50 Eq EIA measures the total classical complement pathway activity in human serum, thereby allowing detection of a deficiency of one or more of the complement components C1 through C9. The CH50 Eq EIA is for laboratory and professional use. ## Device Story The QUIDEL CH50 Eq EIA is an in vitro diagnostic test for quantifying total classical complement pathway activity in human serum. The device uses a three-step process: (1) complement activation by adding serum to microassay wells containing a complement activator; (2) sample dilution and binding of generated terminal complement complexes (TCC) to monoclonal antibody-coated microassay wells; (3) detection via HRP-conjugate and chromogenic enzyme substrate. Absorbance (A405) is measured spectrophotometrically; color intensity is proportional to TCC concentration and CH50 units. Results are expressed in CH50 unit equivalents per milliliter (CH50 U Eq/mL). The test is performed in a laboratory setting by professional staff. By providing a direct measure of TCC, the device aids clinicians in diagnosing immunologic disorders associated with complement component deficiencies, offering an alternative to traditional lytic CH50 hemolytic assays. ## Clinical Evidence Clinical evaluation involved 226 patient samples tested at a major U.S. clinical reference laboratory. Accuracy was assessed via Receiver Operator Curve (ROC) analysis, comparing the device to the combined results of three hemolytic assays and one EIA-based assay. The device demonstrated an overall accuracy greater than 97%. Additional bench testing confirmed intra- and inter-assay precision, lot-to-lot consistency, and lack of interference from potentially interfering substances. ## Technological Characteristics Enzyme-linked immunosorbent assay (EIA) using monoclonal antibodies to capture terminal complement complexes (TCC). Employs HRP-conjugate and chromogenic enzyme substrate for detection. Readout via spectrophotometer (A405). Standardized to CH50 unit equivalents per milliliter. Designed for laboratory use. ## Regulatory Identification A complement components immunological test system is a device that consists of the reagents used to measure by immunochemical techniques complement components C1q , C1r , C1s , C2 , C3 , C4 , C5 , C6 , C7 , C8 , and C9 , in serum, other body fluids, and tissues. Complement is a group of serum proteins which destroy infectious agents. Measurements of these proteins aids in the diagnosis of immunologic disorders, especially those associated with deficiencies of complement components. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Jul 2 9 1998 # 1974111 #### SUMMARY OF SAFETY AND EFFECTIVENESS XI. Product: OUIDEL CH50 Eq EIA ### Manufacturer: QUIDEL Corporation 10165 McKellar Court San Diego, CA 92121 #### Device Classification: The device, QUIDEL CH50 Eq EIA, is similar to other FDA-cleared devices used to measure by immunochemical techniques complement components Clo, C1, C1, C1, C2, C4, C5, C6, C7, C8 and C9 in serum, other body fluids and tissues. Measurements of these proteins aid in the diagnosis of immunologic disorders, especially those associated with deficiencies of complement components (21 CFR 866.5240). The Food and Drug Administration (FDA) published a final regulation in the Federal Register classifying Complement components immunological test system as Class II. #### Intended Use: The QUIDEL CH50 Eq EIA measures the total classical complement pathway activity in human serum, thereby allowing detection of a deficiency of one or more of the complement components C1 through C9. The CH50 Eq EIA is for laboratory and professional use. ### Physiologic Basis for the Test: The classical complement pathway is triggered by the binding of C1q component of C1 to immune complexes. This activation results in a cascade of enzymatic and non-enzymatic reactions, culminating in the formation of terminal complement complexes (TCC). Under standard conditions the level of TCC which can be generated in serum is a quantitative expression of the serum's total classical complement activity. {1}------------------------------------------------ The traditional method for measuring the total classical complement activity in serum is the CH50 test. This test is a lytic assay which uses antibodysensitized sheep erythrocytes (EA) as the activator of the classical complement pathway and various dilutions of the test serum to determine the amount required to give 50% lysis. The percent hemolysis is determined spectrophotometrically. The CH50 test is an indirect measure of TCC, since the TCC themselves are directly responsible for the hemolysis which is measured. The QUIDEL CH50 Eq EIA provides a direct measure of the total classical complement activity in serum by quantifying the amount of TCC generated under standard conditions. The test uses a monoclonal antibody to a unique neoantigen to capture the TCC analyte. Since both the QUIDEL CH50 Eq EIA and the CH50 test rely on the generation of TCC and correlate, the QUIDEL CH50 Eq EIA's results are expressed in CH50 unit equivalents per milliliter. #### Principle of the Test: The OUIDEL CH50 Eq EIA for quantifying the total classical complement activity in human serum involves three basic procedures: (1) complement activation; (2) sample dilution; and, (3) assay for terminal complement complexes (TCC). To activate the classical complement pathway, undiluted human serum samples and the Controls are added to microassay wells containing the complement Activator. During an incubation the classical pathway of complement is triggered and TCC are generated. In the second step, the activated sera are diluted in microassay wells or test tubes and dispensed, together with the Standards, directly into a precoated microassay plate. The TCC present in the activated samples bind to the monoclonal antibodies coating the surface of the microassay wells. In the third step, the TCC microassay plate is washed and loaded with an HRP-conjugate which will bind to the bound TCC. After washing, the TCC microplate is loaded with a chromogenic enzyme substrate. After incubation a reagent is added to stop color development. The absorbancies (A405 values) generated with the Controls, Standards and test specimens are measured spectrophotometrically. The color intensity of the reaction mixture is proportional to the concentration of TCC present and to CH50 units. Using the kit standard curve, assay results are expressed in CH50 unit equivalents per milliliter (CH50 U Eq/mL). {2}------------------------------------------------ ## Safety and Effectiveness: Numerous studies were undertaken to document the performance characteristics and the substantial equivalence of the QUIDEL CH50 Eq EIA to other commercially available products. These studies included the following: - The test was shown to be similar to other commercially available tests in terms of . features and intended use. - The test was shown to have good intra- and inter-assay precision. ● - Lot-to-lot consistency analyses showed the test to be reproducibly manufacturable. ● - Potentially interfering substances were shown not to interfere with the test's . performance. - Two hundred and twenty six (226) patient samples were tested at a major clinical . reference laboratory in the United States and evaluated by Receiver Operator Curve (ROC) Analysis. By this method the overall accuracy of the QUIDEL CH50 Eq EIA, when compared to the combined results from three hemolytic and one EIA-based assay, was greater than 97%. - . Stability studies are underway to establish the shelf-life of the product as its optimal storage and shipping conditions. #### Conclusion: These studies demonstrated the substantial equivalence of the QUIDEL CH50 Eq EIA to existing products already marketed. They further demonstrated the suitability of the product for laboratory and professional use. Such studies are a critical element in establishing the fundamental safety and effectiveness of the product and its appropriateness for commercial distribution. {3}------------------------------------------------ Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized symbol that resembles a person embracing or supporting another person, represented by abstract shapes. Jul 2 9 1998 Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Mr. Edward J. McMullen Manager, Regulatory Compliance Ouidel Corporation 10165 McKellar Court San Diego, California 92121 Re : K974111/S1 Trade Name: QUIDEL CH50 Eq EIA Regulatory Class: II Product Code: DAE Dated: May 29, 1998 Received: June 2, 1998 Dear Mr. McMullen: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Reqister. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations. {4}------------------------------------------------ Page 2 Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a leqally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html" Sincerely yours, Steven Putman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure -------------------------------------------------------------------------------------------------------------------------------------------------------------------- {5}------------------------------------------------ Page _________________________________________________________________________________________________________________________________________________________________________ | 510(k) Number (if known): | K974111 | |---------------------------|---------| |---------------------------|---------| Device. Name: QUIDEL CH50 Eq EIA Indications for Use: . · The QUIDEL CH50 Eq EIA intended to measure the total classical complement pathway activity in human serum, thereby allowing detection of a deficiency of one or more of the complement components C1 through C9. The QUIDEL CH50 Eq EIA is intended for laboratory and professional use. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Clinical Laboratory Device 510(k) Number K974111 | Prescription Use (Per 21 CFR 801.109) | OR | Over-The Counter Use | |---------------------------------------|----|----------------------| |---------------------------------------|----|----------------------| (Optional Format 1-2-96) --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAE/K974111](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DAE/K974111) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com